Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.

Yu, Anthony F; Yadav, Nandini U; Lung, Betty Y; Eaton, Anne A; Thaler, Howard T; Hudis, Clifford A; Dang, Chau T; Steingart, Richard M

Yu, Anthony F; Yadav, Nandini U; Lung, Betty Y; Eaton, Anne A; Thaler, Howard T; Hudis, Clifford A; Dang, Chau T; Steingart, Richard M.

Affiliation

Yu AF; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA, yua3@mskcc.org.

Breast Cancer Res Treat ; 149(2): 489-95, 2015 Jan.

Article in En | MEDLINE | ID: mdl-25552363

Subject(s)

Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Agents/adverse effects; Breast Neoplasms/complications; Breast Neoplasms/metabolism; Heart Failure/etiology; Receptor, ErbB-2/metabolism; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents/therapeutic use; Breast Neoplasms/pathology; Breast Neoplasms/therapy; Cardiotoxicity; Chemotherapy, Adjuvant; Female; Heart Failure/physiopathology; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2/antagonists & inhibitors; Trastuzumab; Ventricular Dysfunction, Left/chemically induced

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized / Heart Failure / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2015 Document type: Article Country of publication: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google